Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women.

This study is looking at blood and cervicovaginal fluid (CVF) samples of healthy volunteers taking raltegravir. The purpose of this study is to measure the extent that raltegravir penetrates into other body compartments, such as the genital tract. Subjects will take the study drug for 7 days, a total of 10 visits to the research center will be required. A screening visit will occur on no more than 28 days On Days 1 and 7 the subject will stay in the research center for approximately 12 hours for scheduled blood and CVF sampling. Days 3-6 and 8-9 will involve a short visit to the research center for one pre-dose blood and CVF sample before the morning dose. A follow up visit will occur about 7-10 days after last dose.

Inclusion criteria

• Healthy pre-menopausal female subjects
• Between the ages of 18 and 49 years
• With an intact uterus and cervix

(Healthy is defined as no irregular menstrual cycles or clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests).

Exclusion criteria

• Negative serum pregnancy test at screening and should be using at least one method of contraception
• Body Mass Index (BMI) of approximately 18 to 30 kg/m^2
• And a total body weight > 50 kg (110 lbs)